JP2023505203A5 - - Google Patents

Info

Publication number
JP2023505203A5
JP2023505203A5 JP2022533368A JP2022533368A JP2023505203A5 JP 2023505203 A5 JP2023505203 A5 JP 2023505203A5 JP 2022533368 A JP2022533368 A JP 2022533368A JP 2022533368 A JP2022533368 A JP 2022533368A JP 2023505203 A5 JP2023505203 A5 JP 2023505203A5
Authority
JP
Japan
Prior art keywords
binding protein
ilt7
pharmaceutical composition
type
ifngs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505203A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063396 external-priority patent/WO2021113702A1/en
Publication of JP2023505203A publication Critical patent/JP2023505203A/ja
Publication of JP2023505203A5 publication Critical patent/JP2023505203A5/ja
Priority to JP2025277753A priority Critical patent/JP2026053543A/ja
Pending legal-status Critical Current

Links

JP2022533368A 2019-12-06 2020-12-04 Ｉｌｔ７結合タンパク質を使用した治療方法 Pending JP2023505203A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025277753A JP2026053543A (ja) 2019-12-06 2025-12-23 Ｉｌｔ７結合タンパク質を使用した治療方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962944845P 2019-12-06 2019-12-06
US62/944,845 2019-12-06
US202063023820P 2020-05-12 2020-05-12
US63/023,820 2020-05-12
US202063024182P 2020-05-13 2020-05-13
US63/024,182 2020-05-13
US202063083649P 2020-09-25 2020-09-25
US63/083,649 2020-09-25
US202063109923P 2020-11-05 2020-11-05
US63/109,923 2020-11-05
PCT/US2020/063396 WO2021113702A1 (en) 2019-12-06 2020-12-04 Methods of treatment using ilt7 binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025277753A Division JP2026053543A (ja) 2019-12-06 2025-12-23 Ｉｌｔ７結合タンパク質を使用した治療方法

Publications (2)

Publication Number Publication Date
JP2023505203A JP2023505203A (ja) 2023-02-08
JP2023505203A5 true JP2023505203A5 (enExample) 2023-12-11

Family

ID=76222037

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533368A Pending JP2023505203A (ja) 2019-12-06 2020-12-04 Ｉｌｔ７結合タンパク質を使用した治療方法
JP2025277753A Pending JP2026053543A (ja) 2019-12-06 2025-12-23 Ｉｌｔ７結合タンパク質を使用した治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025277753A Pending JP2026053543A (ja) 2019-12-06 2025-12-23 Ｉｌｔ７結合タンパク質を使用した治療方法

Country Status (11)

Country Link
US (1) US20220403020A1 (enExample)
EP (1) EP4069288A4 (enExample)
JP (2) JP2023505203A (enExample)
KR (1) KR20220110523A (enExample)
CN (1) CN115135337A (enExample)
AU (1) AU2020395232A1 (enExample)
BR (1) BR112022010786A2 (enExample)
CA (1) CA3159511A1 (enExample)
IL (1) IL293572A (enExample)
MX (1) MX2022006689A (enExample)
WO (1) WO2021113702A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
MX2023013015A (es) 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
AR130042A1 (es) 2022-07-27 2024-10-30 Viela Bio Inc Formulaciones que comprenden una proteína de unión al transcripto 7 similar a inmunoglobulina (ilt7)
WO2024126431A1 (en) * 2022-12-12 2024-06-20 Horizon Therapeutics Ireland Dac Anti-ilt7 binding agents for the treatment and prevention of myositis
WO2024173764A1 (en) * 2023-02-16 2024-08-22 Alumis Inc. Methods of treating hidradenitis suppurativa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
NZ616992A (en) * 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
US20110311558A1 (en) * 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
KR20140048877A (ko) * 2011-04-26 2014-04-24 제넨테크, 인크. 자가면역 질환의 치료를 위한 조성물 및 방법
AU2017231833B2 (en) * 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same

Similar Documents

Publication Publication Date Title
JP2023505203A5 (enExample)
AU2009212216B2 (en) Disease markers and uses thereof
RU2014145058A (ru) Способы лечения, диагностики и мониторинга ревматоидного артрита
EP2077858A2 (en) Interferon alpha-induced pharmacodynamic markers
WO2008137838A2 (en) Interferon alpha-induced pharmacodynamic markers
JP2026053543A (ja) Ｉｌｔ７結合タンパク質を使用した治療方法
JP2013505938A5 (enExample)
JP2022536412A5 (enExample)
CN115667309A (zh) 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
JP2024116343A (ja) ヘパピティスｂウイルス複製およびヘパピティスｂウイルス表面抗原分泌の抑制方法
JP2025087764A5 (enExample)
JP2023549872A5 (enExample)
TW202241945A (zh) 類固醇節制
CN115894691B (zh) 靶向ror1的抗原结合蛋白
WO2016112849A1 (zh) I型干扰素及间充质干细胞在制备抗肿瘤药物中的新用途
JP2019520355A (ja) ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法
RU2845151C1 (ru) Способы лечения с использованием ilt7-связывающих белков
AU2015203772A1 (en) Disease markers and uses thereof
EP2566973A2 (en) Optimized degenerative muscle disease diagnostics and treatments
EP3747470A1 (en) Drug for chronic inflammatory disease and method for evaluating susceptibility to chronic inflammatory disease
AU2023312911A1 (en) Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
JP2014040393A (ja) 遺伝子発現調節剤
Majumdar et al. Antigenic Evaluation of HEV ORF-2 Peptide by MTT Assay
JPWO2012077774A1 (ja) 全身性エリテマトーデスの予防・治療装置
KR20260060447A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법